Saturday 17 October 2026
Export GDTC’s income statement to Excel — free account
CytoMed Therapeutics Limited
GDTC Healthcare Biotechnology
CytoMed Therapeutics Limited’s revenue for fiscal 2025 (year ended December 2025) was $252,300.00, up 395.7% from fiscal 2024. Insiders bought in the last twelve months.
0.88
0.01
+1.15%
Follow GDTC
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% |
+7 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (9.19) | (8.47) | (8.45) | |
Capital Expenditures |
— | (2.22) | (1.77) | (1.51) | |
| Other line items | |||||
Cash ROIC |
0.00% | (125.55%) | (102.09%) | (79.80%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.18 | 0.29 | 0.22 | |
Capex/Depreciation |
— | (2.71) | (2.22) | (1.87) | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026